Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it…
Medical Affairs: An Orchestra, Not a Horse Race
Every horse race has a starting bell, a push to move as fast as possible, and a…
Three Big Mistakes
Over the past 20 years, The NemetzGroup has been involved in the launch of more…
Spotlight on Transitions
This topic of “transition” came home to me (literally and figuratively) over the Thanksgiving holiday. With our adult kids returning, my husband and…
Networking in Biopharma: Four Ways to Build Better Relationships
Networking! You know, that activity that one either embraces or goes running away from as quickly as possible. For many, the word evokes a grueling,…
Biopharma Brand Team and Launch Team Structure: A Practical Guide
For those of you following closely (thank you!), you may recall that in an earlier e-conversation — 21st Century Commercialization — More than a…
Are Your Assumptions Serving You Well?
Ah, June, the season of life transitions — weddings, graduations, school progression and, with the year nearly half over, a reminder to reflect on…
The Future of Biopharma Commercialization Strategy Is Now
Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO,…
Biopharma Launch Planning for Emerging Companies: Four Key Challenges
Living in a parallel universe, launching a company and drug simultaneously.
Tales from the Healthcare Front Lines
Each month, you have given our team permission to communicate our views on the biopharma industry, its leadership, and overall commercialization of…
Does Boston Biotech Have a Career Navigation Problem?
For those of us who have been in the industry since pre-DRG days, and have the wisdom and experience across the industry, there are many…